

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10582704
		Filing Date	2004-12-14
		First Named Inventor	Maria Isabel Crespo Crespo
		Group Art Unit	1624
Examiner Name	Deepak Rao		
Sheet	1 of 3	Attorney Docket Number	LABO-003/02US 311815-2022

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US- 4725600	1988-02-16	TAKAYA, et al.	
		US- 5138058	1992-08-11	GEISEN, et al.	
		US- 6156755	2000-12-05	GEISEN, Karl	
		US- 6518424	2003-02-11	JOHN, et al.	
		US- 6562811	2003-05-13	MURATA, et al.	
		US- 6586441	2003-07-01	BORRONI, et al.	
		US- 6716851	2004-04-06	CAI, et al.	
		US- 6844347	2005-01-18	SCHINDLER, et al.	
		US- 20010027196	2001-10-04	BORRONI, EDILIO MAURIZIO, et al.	
		US- 20030078271	2003-04-24	BLACKBURN, et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		EP0407899	1991-01-16	Hoescht, AG		
		EP0459830	1991-12-04	The Wellcome Foundation Ltd.		
		EP0767170	1997-04-09	Taiho Pharmaceutical Co.		
		JP06192252	1994-07-12	Nissan Chemical Ind. Ltd.		
		JP11158073	1999-06-15	Takeda Chem. Ind. Ltd.		
		JP2001089452	2001-04-03	Sankyo Co.		
		JP2001199982	2004-07-24	Dainippon Pharmaceutical Co.		
		JP2003206230	2003-07-22	Yamanouchi Pharma. Co. Ltd.		
		JP54115384	1979-09-07	Hokko Chem. Ind. Co.		
		JP54117029	1979-09-11	Hokko Chem. Ind. Co.		
		JP54147921	1979-11-19	Hokko Chem. Ind. Co.		
		WO01047921	2001-07-05	Pharmacopeia Inc.		
		WO02022602	2002-03-21	Vertex Pharmaceuticals Inc.		
		WO03035639	2003-05-01	Eisai Co. Ltd.		
		WO03049739	2003-06-19	Vertex Pharmaceuticals Inc.		
		WO03068757	2003-08-21	F. Hoffman-La Roche AG		
		WO03077656	2003-09-25	Ciba Specialty Chemicals Holding Inc.		
		WO04014307	2004-02-19	Synaptic Pharmaceutical Corp.		
		WO2004048365	2004-06-10	Chiron Corporation		
		WO2005033084	2005-04-15	Universiteit Leiden		
		WO2005033085	2005-04-15	Universiteit Leiden		
		WO2006110884	2006-10-19	Neurocrine Biosciences, Inc., Almirall		
		WO2007084914	2007-07-26	Neurocrine Biosciences, Inc., Almirall		
		WO2008070661	2008-06-12	Neurocrine Biosciences, Inc., Almirall		
		WO9824782	1998-06-11	Amgen Inc.		

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/

Please type a plus sign (+) inside this box ➡ +

PTO/SB/08A (07-05)
Approved for use through 07/31/2006. OMB 0651-0031

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10582704
		Filing Date	2004-12-14
		First Named Inventor	Maria Isabel Crespo Crespo
		Group Art Unit	1624
		Examiner Name	Deepak Rao
Sheet	2 of 3	Attorney Docket Number	LABO-003/02US 311815-2022

OTHER – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		BARALDI, P. G., et al., Pyrazolo{4,3,e}-1,2,4-triazolo-{1,5-c}pyrimidine Derivatives as highly potent and Selective A3 Adenosine Receptor Antagonists: Influence of the Chain at the N8 Pyrazolem Nitrogen. Journal of Medicinal Chemistry, 2000, 4768-4780, 43.	
		BARALDI, P. G., et al., Pyrazolo{4,3,e}-1,2,4-triazolo-{1,5-c}pyrimidine Derivatives: potent and Selective A2a Adenosine Antagonist. Journal of Medicinal Chemistry, 1996, 1164-1171, 39.	
		BREDERECK, Helmut, et al. Trisacylaminomethane: Synthesen und Umsetzungen, Chem Ber, 1963, 1505-1514, 96.	
		BROWN, D. J. et al., Heterocyclic Amplifiers of Phenomycin. I. Some Pyrimidinylpurines, Pyrimidinylpteridines and Phenylpyrimidines. Journal of Chemistry, 1984, 155-163, 37.	
		CHANG, Lisa C. W., et al., 2, 4, 6-Trisubstituted Pyrimidines as a New Class of Selective Adenosine A1 receptor Antagonists, J. Med. Chem., 2004, 6529-6540, 47.	
		CHAPMAN, N. B., et al., Nucleophilic Displacement Reaction sin Aromatic Systems Part III. J Chem Soc., 1954, 1190-1192.	
		CHENG, et al., Biochem. Pharm. 22:3099-3108, 1973.	
		CONDRET, C. Synthetic Communications 1996, Vol. 26, No. 19, p. 3543-3547.	
		DALL'IGNA, et al., "Caffeine and adenosine A2a receptor antagonists prevent β -amyloid (25-35)-induced cognitive deficits in mice" Experimental Neurology, 2007; Vol. 203, p. 241-245.	
		Database Crossfire Beilstein Beilstein Institut Zur Foederung Der Chemischen Wissenschaften, Frankfurt AM Main, De; Dataase-Accession No. 2983888 (BRN) XP002495819 Abstract & Justus Liebig's Annalen Der Chemie, Vol. 704, 1967, p. 144-149, DE.	
		DEVALK, J. et al., On the Mechanism of the Amination of 2-Bromo-2,6-diphenyl-pyrimidine with Potassium Amide in Liquid Ammonia. Recueil, 1973, 155-163, 92.	
		EL-SHENAWY, A. I. et al., Synthesis of Some Heterocyclic Compounds Bearing a Maleimido Moiety, Egyptian Journal of Chemistry, 2002, 895-904, 45.	
		European Application EP06750082.7 Office Action mailed 04.28.09.	
		European Application EP06750082.7 Office Action mailed 09.18.08	
		European Application EP04814183.2 Office Action mailed 03.09.10.	
		European Application EP04814183.2 Office Action mailed 08.04.09.	
		European Application EP04814183.2 Office Action mailed 09.03.10.	
		European Application EP07718002.4 Office Action mailed 04.01.09	
		European Application EP07718002.4 Office Action mailed 10.14.10	
		European Application 08732707.8 Office Action mailed 02.16.10.	
		FAROUK H. et al., "Reaction of alpha,beta-unsaturated ketones with guanidine. Substituent effects on the protonation constants of 2-amino-4,6-diarylpyrimidines." J. Heterocyclic Chem., 1982 1087-1092, 19.	
		FREDHOLM, B. B., et al., International Union of Pharmacology.XXV. Nomenclature and Classification of Adenosine Receptors. Pharmacological Reviews 2001, p. 527-552, 53.	
		GOTOR, Vincente, et al., Synthesis and Rearrangement of 5-Isocyanatopyrazolines, Tetrahedron, 1989, 1783-1792, 45.	
		HENZE, et al., Researches on Pyrimidines: Certain Derivatives of 2-Propylpyrimidine, J. Amer. Chem. Soc. 1957, 2230-2232, 79.	
		HESS, S., et al., &-Deazaadenines Bearing Polar Substituents; Structure-Activity Relationships of New A1 and A3 Adenosine Receptor Antagonists. Journal of Medicinal Chemistry, 2000, 4636-4646, 43.	
		Israel Patent Application 176,005 Office Action dated on or around 01.16.09.	

2.
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/
/Deepak Rao/ 12/17/2010

Please type a plus sign (+) inside this box → +

PTO/SB/08A (07-05)
Approved for use through 07/31/2006. OMB 0651-0031

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10582704
		Filing Date	2004-12-14
		First Named Inventor	Maria Isabel Crespo Crespo
		Group Art Unit	1624
		Examiner Name	Deepak Rao
Sheet	3 of 3	Attorney Docket Number	LABO-003/02US 311815-2022

		KABBE, "Substituierte 4-Hydroxy-und 4-Amino-Pyrimidine" JUSTUS LIEBIGS ANNALEN DER CHEMIE, Vol. 704, 1967, p. 144-149, XP008090403.	
		KIM, et al. "Modeling the Adenosine Receptors: Comparison of the Binding Domains of A2A Agonists and Antagonists" Journal of Medicinal Chemistry, Nov. 6, 2003, LNKD-PUBMED: 14584936, ISSN: 0022-2623, Vol. 46, No. 23, Nov. 6, 2003, p. 4847-4859.	
		LARDENOIS Patrick et al, Tautomerie des composes heterocycliques. Bulletin de la Societe de Chimique de France, 1971, 1858-1868.	
		MAMAEV, V. P., et al., New Method for the Synthesis of 2-Aminopyrimidines, Chem. Heterocycl. Compd. 1975, 1322-1324, 11.	
		Mexico Patent Application PA/z/2006/006776 Office Action dated on or around 07.28.09.	
		MULLER, C. E. "A2A Adenosine Receptor Antagonists - Future Drugs for Parkinson's Disease?" Drugs of the Future, Prous Science, ES LnkD - DOI: 10.1358/DOF.2000.025.10.858696, Vol. 25, No. 10, 1 January 2000 (2000-01-01), p. 1043-1052, XP008035142 ISSN: 037	
		PCT Application PCT/US2004/041970 International Search Report, IPRP and WtOp mailed 04.20.05	
		PCT/US2007/086380 IPRP and Written Opinion mailed 06.10.09.	
		PCT/US2007/086380 ISR mailed 04.22.08.	
		PCT/US2008/057911 IPRP and Written Opinion 10.01.09.	
		PCT/US2008/057911 ISR mailed 01.16.09.	
		PRIEGO, E. M., et al., Pyrido[2, 1-f]purine-2,4-dione Derivatives as a Novel Class of Highly Potent A3 Adenosine Receptor Antagonists. Journal of Medicinal Chemistry, 2002, 3337-3344, 45.	
		SARGES, R., et al., 4-Amino[1,2,4]triazolo[4,3-a]quinazolines. A Novel Class of Potent Adenosine Receptor Antagonists and Potential Rapid-Onset Antidepressants. Journal of Medicinal Chemistry, 1990, 2240-2254, 33.	
		TYRELL, E. et al., Synthesis 2003 Vol 4, p. 469-483	
		VAN GALEN, P. J., et al., Imidazo[4,5-c]quinolin-4-amines: Novel Xanthine Adenosine Agonists. Journal of Medicinal Chemistry, 1991, p. 1202-1206, 34.	
		WHEELER, Henry L., Researches on Poyrimidines: On Some Salts of Cytosin, Isocytosin, 6-Aminopyrimidin and 6-Oxypyrimidin, J Biol Chem 1907, 285-297, 3.	
		ZHANG, J. Org. Chem., 2005, 70, 5164.	

Examiner Signature	/Deepak Rao/	Date Considered	12/17/2010
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Unique citation designation number (optional). ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/